pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BAUSCH · news · pharmadog
← back to BAUSCH
News mentioning BAUSCH
17
stories
16d
Next-gen RNAi drugmaker City prices $200M IPO
biopharma dive
16d
City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq
fiercebiotech
17d
Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
fiercebiotech
20d
Brent Saunders out as Bausch + Lomb CEO, an abrupt end to three-year run
endpoints
20d
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
biopharma dive
Sep 25, 26
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
Sep 16, 26
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
biospace
Sep 15, 26
FDA warns Bausch and Lomb, Indian API maker for GMP issues
raps
Aug 26, 26
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
biopharma dive
Aug 25, 26
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail
biospace
Aug 24, 26
Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal
endpoints
Aug 5, 26
Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
fiercebiotech
Aug 3, 26
STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
stat
Jul 15, 26
STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states
stat
Jul 10, 26
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
endpoints
Jun 10, 26
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
biopharma dive
Jun 8, 26
City banks nearly $100M for next-gen RNAi drugs
biopharma dive
